SCHEMBL23190189

SCHEMBL23190189

CN(C)C(=O)c1ccc(-c2nn(-c3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)c3cncc(N)c23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 4/20 0.51
▸ FLT3 P36888 10/20 0.50
▸ LCK P06239 1/20 0.50
▸ CSF1R P07333 1/20 0.50
▸ RET P07949 1/20 0.50
▸ PDGFRB P09619 1/20 0.50
▸ KIT P10721 1/20 0.50
▸ PDGFRA P16234 1/20 0.50
▸ CDK11B P21127 1/20 0.50
▸ CCNC P24863 1/20 0.50
▸ FLT4 P35916 1/20 0.50
▸ CDK8 P49336 1/20 0.50
▸ BTK Q06187 1/20 0.50
▸ DDR1 Q08345 1/20 0.50
▸ DDR2 Q16832 1/20 0.50
▸ MKNK2 Q9HBH9 1/20 0.50
▸ KDR P35968 3/20 0.48
▸ MAPK14 Q16539 1/20 0.44
▸ RIPK1 Q13546 1/20 0.44
▸ MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23190201 0.92 FLT3 (0.51) RAF1FLT3LCKCSF1RRET
SCHEMBL23190194 0.89 FLT3 (0.51) RAF1FLT3LCKCSF1RRET
SCHEMBL23190198 0.89 FLT3 (0.48) RAF1FLT3LCKCSF1RRET
SCHEMBL23190193 0.88 FLT3 (0.50) RAF1FLT3LCKCSF1RRET
SCHEMBL23190199 0.86 FLT3 (0.48) RAF1FLT3LCKCSF1RRET
SCHEMBL23190191 0.86 FLT3 (0.55) RAF1FLT3LCKCSF1RRET
SCHEMBL20873187 0.85 FLT3 (0.68) FLT3LCKCSF1RRETPDGFRB
SCHEMBL23190196 0.84 FLT3 (0.51) RAF1FLT3LCKCSF1RRET
Iodide SCHEMBL23190190 0.84 FLT3 (0.56) RAF1FLT3LCKCSF1RRET
SCHEMBL23190195 0.84 FLT3 (0.48) RAF1FLT3LCKCSF1RRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975082-B2 Inhibitor of FLT3 kinase and use thereof PRECEDO PHARMACEUTICALS CO., LTD (CN) 2021-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975082-B2 Inhibitor of FLT3 kinase and use thereof FLT3, FLT1, FGFR1 RAF1 45/4885FLT3 1/4885LCK 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback